(Bloomberg) — CureVac AG, a player in the hotly contested race for a coronavirus vaccine and soon to be partly owned by the German government, is working with Bank of America Corp. and Jefferies Financial Group Inc. on a U.S. initial public offering, according to people familiar with the matter.The vaccine maker, based in Tuebingen, Germany, could raise $150 million to $200 million, valuing the company at $1 billion, said the people, who asked not to be identified because the information wasn’t public. That valuation could change depending on whether regulators approve a vaccine.CureVac Chief Financial Officer Pierre Kemula said …read more
Source:: Yahoo Finance
